2021 was a landmark year for private capital fundraising across many sectors with the excitable market allowing for plentiful, early exits. The biopharma industry saw particular interest as the COVID-19 pandemic drew attention to potential gains to be made from the sector. Has the appetite for investing in drug development waivered now the pandemic has subsided?
Private Equity And VC Fund Data: What Do The Numbers Show?
In Vivo examines trends in the venture capital and private equity funding landscapes for biotech and pharma – looking at both expenditure and gathering of capital resources.
More from Deal-Making
• By
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
An interactive look at pharma, medtech and diagnostics deals made during February 2025. Data courtesy of Biomedtracker.
More from In Vivo
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.
• By
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.